Highlights

  • Second quarter revenue rose 7.7% to $49.0 million, led by 14.8% growth in Life Sciences Services.
  • The GAAP loss from continuing operations narrowed to $8.3 million from $12.0 million a year earlier.
  • Cryoport supported 779 clinical trials, 94 of them in Phase 3, plus 22 commercial therapies at June 30.
  • Management affirmed 2026 revenue guidance of $192 million to $196 million on its August 6 call.

Cryoport, Inc. (NASDAQ:CYRX) shares were trading near their 52-week high at USD 18.47 on October 21, 2026, up 5.88%. The temperature-controlled supply chain company reported second quarter results on August 6, with higher revenue, a smaller loss and unchanged full-year revenue guidance.

Cryoport lists its principal executive offices in Brentwood, Tennessee, and is a Nevada corporation. It describes itself as a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on cell and gene therapy. It reports two segments: Life Sciences Services, which covers logistics, biostorage, bioservices and cryopreservation; and Life Sciences Products, which makes cryogenic freezers, dewars and accessories. Its customers include biopharmaceutical companies, animal health and reproductive medicine providers, academic institutions and government agencies. Its fiscal year ends December 31.

Services Growth Offsets Flat Product Sales

Revenue for the three months ended June 30, 2026 was $49.0 million, up from $45.5 million. Life Sciences Services revenue grew 14.8% to $28.0 million, with BioLogistics Solutions up 12.5% to $22.4 million and BioStorage/BioServices up 24.8% to $5.6 million. Commercial cell and gene therapy revenue within services rose 26.5% to $9.4 million. Life Sciences Products revenue was $21.0 million, down 0.4%.

Gross margin was $22.8 million, or 46.6% of revenue, against 47.0% a year earlier. Services margin improved to 49.9% from 48.9%, while product margin eased to 42.2% from 44.9%, which management tied to product mix. Selling, general and administrative expense rose 4.1% to $28.0 million and engineering and development rose 17.8% to $4.9 million. Investment income doubled to $3.1 million.

The loss from continuing operations was $8.3 million, compared with $12.0 million a year earlier. After a $2.0 million paid-in-kind dividend on Series C convertible preferred stock, the net loss attributable to common stockholders was $10.3 million, or $0.20 per share. The prior-year quarter showed net income of $106.9 million, or $2.13 per share, because of $120.9 million of income from discontinued operations tied to the June 2025 sale of the CRYOPDP business to DHL for $133.0 million. For six months, revenue rose 11.9% to $96.8 million and the net loss was $18.8 million. Management cited adjusted EBITDA, a non-GAAP measure, of about $0.4 million for the quarter, a $1.3 million improvement.

Clinical Pipeline, Cash and the 2026 Notes

At June 30, Cryoport supported 779 clinical trials, up 51 from a year earlier, of which 94 were in Phase 3. It also supported 22 commercial therapies. For the rest of 2026, management said it anticipates another 11 possible regulatory filings for cell and gene therapies, five more therapy approvals and one label or geographic expansion. New supply chain centers in France and California are scheduled to open in the fourth quarter.

Cash and cash equivalents were $269.3 million, with $127.4 million of short-term investments and working capital of $239.2 million. Operating cash flow for the six months was positive $4.9 million, compared with negative $11.7 million a year earlier. Capital expenditures were $19.1 million.

The company had about $186.2 million of 2026 Convertible Senior Notes outstanding, due in December 2026, and expects to repay them at maturity. It says cash, investments and projected cash flows should satisfy its needs for at least twelve months on that basis, but acknowledges it expects operating losses in the near term and may need additional capital for operations or acquisitions until profitability is sustained. No shares were repurchased in the six months, and about $63.9 million remained under its 2024 repurchase authorization.

Affirmed 2026 Guidance and Priorities

Management affirmed 2026 revenue guidance of $192 million to $196 million, and the chief executive said holding the range reflected geopolitical and macroeconomic uncertainty. Management said it expects the first-half demand trends to continue and anticipates further operating leverage as use of its global supply chain centers rises. It also described a path toward profitability, and said it began producing freezers in China during the quarter. These are company expectations, not completed results.